Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100 India
T 91 80 2808 2808
F 91 80 2852 3423

www.biocon.com

Ref: Bio/Acts/ CS/ SE/ Ltrs- NSE/11
January 01, 2014

The National Stock Exchange of India Limited
Exchange Plaza
Bandra – Kurla Complex
Bandra (East)
Mumbai- 400 051

"By Email & Courier"

Kind Attn: **Mr. Hari K.**

Dear Sir,

Subject: Intimation of Press Statement

Please find enclosed a copy of press statement being issued by the Company today.

Kindly take this intimation on record.

Thanking you,
Yours faithfully,
For Biocon Ltd,

by "Courier"
by Fax To NSE: 022 – 2659 8237 / 38
NSE: cmlist@nse.co.in

Kiran Kumar G
Company Secretary
E: Kiran.Kumar@biocon.com
T: +91 80 2808 2037

Encl. No of sheets: Cover + 2 Pages

Biocon

Press Statement

Bangalore, India, January 1, 2014

Biocon, Asia's leading biotechnology company, announced today that Rakesh Bamzai, President - Marketing, has decided to leave the organization and accept a new leadership role.

"In his 19 years with the company, Rakesh has played a pivotal role in Biocon's evolution from a leading enzymes company to a global biopharmaceutical enterprise of great repute. As part of the core management of the company, Rakesh was instrumental in creating Biocon's global footprint and building a team of capable individuals to take up higher challenges in the organization.

Rakesh has decided to take up a very senior and challenging leadership assignment and we wish him the best for the future. While his presence will be missed, we firmly believe that he will continue to be a strong brand ambassador for the company going forward," **said Ms Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon.**

Rakesh Bamzai said: *"I have immensely enjoyed my time at Biocon, which has been my home for nearly two decades. I have no doubt that I will remain engaged with Biocon in the future. I am confident that the team I leave behind will ensure Biocon's continued success."*

About Biocon

Established in 1978, Biocon Limited, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patients worldwide. Biocon's robust product portfolio includes the world's first Pichia-based recombinant human Insulin, INSUGEN®, Glargine, BASALOG® and India's first biologic BioMAb-EGFR ™ for head & neck cancer. It has now successfully developed its second novel biologic Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, introduced as Alzumab™ for psoriasis in India, in 2013. For additional information please visit: www.biocon.com

Biocon Media Contacts:	
Seema Ahuja Head-Corporate Communications +91 9972317792 seema.ahuja@biocon.com	**Rumman Ahmed** Manager-Corporate Communications +91 98451 04173 rumman.ahmed@biocon.com